Supernus Pharmaceuticals Inc

SUPN

Market Cap$1.75B

Close$

Compare Supernus Pharmaceuticals

	P/E Ratio	Dividends	Return on Equity	Price-to-Sales	Debt-to-Equity
Supernus Pharmaceuticals Inc	1330.9	0%	0%	2.6	-
Market Avg	59.7	1.27%	30%	-	0.9
Healthcare Avg	64.5	1.29%	15%	7.1	0.8

$39.00

Target Price by Analysts

35.1% upsideSupernus Pharmaceuticals Target Price Details

$76.87

Current Fair Value

166.3% upside

Undervalued by 166.3% based on the discounted cash flow analysis.

Share Statistics

Market cap	$1.75 Billion
Enterprise Value	$1.50 Billion
Dividend Yield	$0.0 (0.0%)
Earnings per Share	$0.02
Beta	0.77
Outstanding Shares	54,734,956
Avg 30 Day Volume	445,195

Return

Return on Equity	-
Return on Assets	-
Return on Invested Capital	-

Valuation & Multiples

P/E Ratio	1330.94
PEG	-1395.28
Price to Sales	2.62
Price to Book Ratio	1.8
Enterprise Value to Revenue	2.46
Enterprise Value to EBIT	111.66
Enterprise Value to Net Income	1137
Total Debt to Enterprise	0
Debt to Equity	0

Revenue Sources

No data

ESG Score

No data

About Supernus Pharmaceuticals Inc

CEO: Jack Khattar